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Abstract
Background: Circulating microRNAs (miRNAs) have been proved to serve as biomarkers for 
diagnosis and assessment of prognosis of coronary artery disease (CAD). Reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) is a widely-used technique to estimate expres-
sion levels of circulating miRNAs. Selection of optimal endogenous control (EC) remains critical 
to obtain reliable qPCR data of miRNAs expression. However, reference controls for normaliza-
tion of circulating miRNA in CAD are still lacking. The purpose of this study was to identify 
stably expressed miRNAs to normalize RT-qPCR data derived from plasma in stable CAD.
Methods: We identified 10 stably expressed candidate ECs by combining miRNA microarray 
screening and literature screening. These 10 candidate ECs were estimated by RT-qPCR and 
the data were analyzed by NormFinder and BestKeeper algorithm. 
Results: Two most stable ECs were identified as EC candidates and they were subsequently 
validated in another larger cohort. The 2 candidates were also validated by normalizing the 
expression levels of miR-21. In general, they were superior to the commonly used reference gene 
RNU6 in quantification cycle (Cq) value, stability value and normalization effect. 
Conclusions: Our results demonstrated that miR-6090 and miR-4516 can be used as refer-
ence genes for plasma miRNA analysis in stable CAD. (Cardiol J 2016; 23, 6: 694–703)
Key words: stable coronary artery disease, circulating microRNA, reverse  
transcription quantitative polymerase chain reaction (RT-qPCR), reference 
genes, normalization
Introduction
Coronary artery disease (CAD) remains 
a major public health issue. The growing social and 
economic burdens have stimulated the interest of 
searching novel biomarkers for disease diagnostics, 
prognostication and monitoring. MicroRNAs (miR-
NAs) are small non-coding RNA molecules which 
have key post-transcriptional regulatory roles in 
many diseases [1]. Dysregulation of miRNAs has 
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been detected in a wide range of diseases, such as 
cardiovascular disease [2], cancer [3], and tissue 
injury [4]. In the past few years, scientists have 
found that miRNA can be rapidly released from 
tissues into the circulation with the development 
of pathology, and exist in a highly stable, cell-free 
form in body fluids such as plasma [5], serum [6], 
and urine [7]. These findings have inspired a great 
interest in using extracellular circulating miRNAs 
as non-invasive biomarkers for molecular diagnos-
tics and prognostics [8].
Reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) is a widely-used ap-
proach to estimate expression levels of circulating 
miRNAs [9]. Accurate quantitation of miRNA levels 
is necessary for their use as biomarkers and in de-
termining their functions, which can be affected by 
sample collection, sample storage, RNA isolation, 
RT and PCR efficiency. A suitable normalization 
can minimize measurement errors and technical 
variability in experiments. Therefore, the choice 
of normalization method plays an instrumental role 
and needs to be strongly considered. However, to 
date, there is no consensus on normalization of 
circulating miRNA in qPCR amplification.
One of the main challenges in quantifying 
circulating miRNA expression is that the concen-
tration of total RNA extracted from plasma is often 
close to, or below, the detection limit of NanoDrop 
spectrophotometer (< 50 ng), making it difficult to 
measure and equalize miRNA input levels before 
analysis by RT-qPCR. Thus, standard methods for 
measurement of the RNA yield and quality are inap-
propriate for biofluid samples. Endogenous refer-
ence miRNA [10–12], exogenous spike-in artificial 
synthetic oligonucleotide [13], and the mean global 
expression [14] have been described to be used in 
normalization of circulating miRNAs. The selection 
of suitable endogenous controls (ECs), with which 
to normalize RT-qPCR data, is currently the most 
commonly used method for the determination of 
miRNA expression levels. Circulating miRNAs 
expression is greatly influenced by the different 
pathology, so there is no reference miRNA which 
can be suitable for all types of samples. Thus, 
researchers have to choose appropriate reference 
genes according to different study populations. To 
the best of our knowledge, currently, there is no 
consensus on reference miRNAs for qPCR analysis 
of plasma miRNAs in CAD. Herein, we have identi-
fied and characterized 2 stable reference genes for 
normalizing plasma miRNAs in stable CAD patients 
and healthy controls. 
Methods
Study cohort and sample collection
Stable CAD patients (50–75 years old) were 
recruited at the First Hospital of Hunan Univer-
sity of Chinese Medicine, Changsha, China. Blood 
from healthy participants (50–75 years old) was 
also collected during physical examinations per-
formed at the First Hospital of Hunan University 
of Chinese Medicine, Changsha, China. Stable 
CAD was defined according to 2012 ACCF/AHA 
practice guideline for stable ischemic heart disease. 
Patients presented typical angina, history of CAD 
and/or positive electrocardiography (ECG) stress 
test, and were confirmed by coronary angiography 
to have a > 70% coronary artery stenosis. The se-
rum levels of creatine kinase of the subjects were 
normal. The control subjects had a normal ECG and 
no history of arterial hypertension, angina, CAD or 
peripheral artery disease. General exclusion crite-
ria were autoimmune or malignant diseases, acute 
infections and severe hepatic or renal diseases. 
Written informed consents were obtained from 
all participants for the use of their venous blood 
samples in this study. Ethical approval was granted 
by the ethics committee of the Hunan University of 
Chinese Medicine. Relevant clinical characteristics 
and sample sets were shown in Table 1.
Venous blood samples (5 mL per subject) were 
collected from each donor into EDTA-containing 
tubes and processed for plasma isolation within 
3 h post-collection. To obtain plasma, samples 
were centrifuged at 3000 rpm for 10 min at room 
temperature, followed by 8000 rpm for 10 min at 
4℃ to completely remove cell debris. The super-
natants were transferred into RNase-free tubes, 
and the plasma samples were stored at −80°C 
prior to RNA extraction. Plasmas with pink/red 
discoloration were considered to be hemolyzed 
and were excluded.
Isolation of total RNA
Total RNA was extracted and purified using 
miRNeasy®Mini kit (Qiagen, German), following 
the manufacturer’s instructions. RNA concentra-
tions were determined with a NanoDrop 1000 
(Thermo Scientific, Wilmington, USA). In general, 
RNA concentrations 8–15 ng/μL, and 100 ng of 
total RNA per sample were used in the subsequent 
miRNA microarray.
Plasma sample of 300 μL was mixed with 
TRIzol®LS reagent (Invitrogen, USA) with a ratio 
of 1:3 in 1.5 mL microcentrifuge tube, and incu-
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bated at room temperature for 5 min. Then, 250 μL 
chloroform was added and mixed vigorously by 
vortex. Incubated at room temperature for 15 min 
and centrifuged at 12,000 rpm for 15 min at 4°C. 
The supernatant (500 μL per tube) was transferred 
to an Eppendorf tube. Subsequently, the RNA was 
precipitated by adding 250 μL isopropanol to the 
aqueous phase. After being incubated at room tem-
perature for 10 min and centrifuged at 12,000 rpm 
for 10 min at 4°C, the RNA pellet was rinsed, air-
dried, and then resuspended in 23 μL RNAase-free 
water. RNA concentration was determined with 
a NanoDrop 1000 (Thermo Scientific, Wilmington, 
USA). This RNA was used in the subsequent RT-
-qPCR. The low RNA concentration precluded the 
reliable assessment of RNA purity by A260/A280 
and A260/A230 absorbance ratios, and it was also 
too low for assessment of RNA integrity by Agilent 
Bioanalyzer “RIN” number.
miRNA microarray hybridization
To assess the expression level of plasma 
miRNA, microarrays from Agilent Technologies 
were used according to manufacturer’s protocols. 
In brief, 100 ng of total RNA was dephospho-
rylated with calf intestinal alkaline phosphatase 
(CIP) at 37°C for 30 min, followed by denaturing 
with dimethyl sulfoxide (DMSO). Then the 3’end of 
dephosphorylated single-stranded RNA (including 
miRNA) was ligated with cyanine 3-cytidine bis-
phosphate (pCp) by T4 RNA ligase. Micro Bio-Spin 
6 columns were used to purify the labeled RNA 
through removing DMSO and free cyanine3-pCP. 
Human miRNA slides were hybridized with the 
purified Cy3-labeled miRNA probes in hybridi-
zation oven at 55°C, 10 rpm for 20 h. After the 
hybridization, slides were washed in Agilent Gene 
Expression wash buffer with Triton X-102. Slides 
were scanned by Agilent Microarray Scanner and 
Feature Extraction software10.7 (Agilent Tech-
nologies, US) with default settings. Raw data were 
normalized by Quantile algorithm, Gene Spring 
Software 12.6 (Agilent Technologies, US).
RT-qPCR analysis
Reverse transcription was carried out using an 
all-in-oneTM miRNA first-strand cDNA synthesis kit 
(Genecopoeia, USA) according to manufacturer’s 
protocols. A universal Oligo-dT adaptor primer was 
used. In brief, the reaction mixture consisted of 
5 μL 5 × reaction buffers, 1 μL RTase Mix, 1 μL 
2.5 U/μL Poly(A) polymerase, and 18 μL total RNA 
solution, in a total volume of 25 μL. Mixture was 
incubated at 37°C for 60 min and 85°C for 5 min.
Quantitative polymerase chain reaction was 
immediately performed by using an all-in-oneTM 
miRNA qPCR Kit (GeneCopoeia, USA) accord-
ing to the manufacturer’s instructions. The ex-
pression levels of miRNA were confirmed with 
a SYBR-based qPCR using individual miRNA- 
Table 1. Clinical characteristic of subjects.
Variable Sample set 1  
(array)
Sample set 2  
(RT-qPCR)
Sample set 3  
(RT-qPCR)
Sample set 4  
(RT-qPCR)
Patients  
(n = 8)
Controls  
(n = 8)
Patients  
(n = 21)
Controls  
(n = 21)
Patients  
(n = 90)
Controls  
(n = 90)
Patients  
(n = 30)
Controls  
(n = 30)
Age [years]:
£ 60 3 4 8 10 41 47 16 15
> 60 5 4 13 11 49 43 14 15
Sex:
Male 4 4 8 10 40 42 13 16
Female 4 4 13 11 50 48 17 14
BMI [kg/m2] 24.3 ± 3.2 23.5 ± 3.8 24.6 ± 2.8 22.9 ± 3.7 24.1 ± 4.0 23.7 ± 3.3 24.1 ± 2.9 23.9 ± 3.2
SBP [mm Hg] 136 ± 13.9 126.9 ± 9.1 130.4 ± 18.4 134.2 ± 16.5 135 ± 22.5 130 ± 16.3 138.4 ± 12.6 135.1 ± 13.1
DBP [mm Hg] 90 ± 9.3 85.4 ± 5.8 80.1 ± 7.9 83.2 ± 7.4 88.1 ± 10.6 78.4 ± 8.9 83.8 ± 7.2 81.9 ± 6.4
TC [mmol/L] 4.4 ± 1.2 4.5 ± 0.6 6.1 ± 1.1 4.8 ± 1.5 5.6 ± 1.2 4.6 ± 1.5 5.3 ± 0.9 4.7 ± 1.3
HDL [mmol/L] 1.4 ± 0.3 1.4 ± 0.3 1.2 ± 1.1 1.1 ± 0.5 1.3 ± 1.2 1.2 ± 1.1 1.3 ± 0.6 1.3 ± 0.8
LDL [mmol/L] 2.4 ± 0.7 2.1 ± 0.4 3.1 ± 0.5 2.6 ± 0.3 4.2 ± 0.3 3.2 ± 0.4 3.3 ± 0.6 2.9 ± 0.5
GLU [mmol/L] 5.5 ± 1.2 5.2 ± 1.1 5.8 ± 3.6 3.7 ± 2.3 5.6 ± 3.1 4.7 ± 2.6 5.0 ± 2.5 4.8 ± 2.1
BMI — body mass index; DBP — diastolic blood pressure; GLU — glucose; HDL, high-density lipoprotein; LDL — low-density lipoprotein;  
SBP — systolic blood pressure; TC — total cholesterol
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-specific primers (GeneCopoeia, USA). The RT-qPCR 
was performed in triplicate for each miRNA, and 
a non-template control was included on the same 
plate. The qPCR reaction mixture consisted of 
10 μL 2 × all-in-one qPCR Mix, 0.5 μL all-in-one 
miRNA qPCR primer, 0.5 μL universal adaptor 
primer, 0.4 μL 50 × ROX reference dye, 7.6 μL 
RNase-free Water and 1 µL cDNA. Amplification 
was performed on the StepOnePlus™ Real-Time 
PCR System (Applied Biosystems, USA).
Data analysis
Statistical analyses were performed with SPSS 
17.0 statistical software. The unpaired student’s 
t-test (for parametric data) or Mann-Whitney 
U-test (for non-parametric data) was used for two- 
-group comparisons. All tests were performed 
two-sided and a significance level of p < 0.05 was 
considered statistically significant. Selection of op-
timal reference gene was conducted using two com-
monly used software programs: NormFinder [15] 
and BestKeeper [16].
Results
Detection of the linear relationship  
between Cq values and plasma volumes  
in qPCR amplification 
To evaluate the range of detectable quantifi-
cation cycle (Cq) values, we first extracted total 
RNA from different volumes of plasma ranging 
from 50 μL to 400 μL (n = 5, volume equal to 50, 
100, 200, 300 and 400 μL, respectively). Then we 
examined miR-6090 in those samples and plotted 
the regression curve. The RT-qPCR assay showed 
a good linear relationship (R2 = 0.9694) when the 
Cq values were between 25 and 45 (Fig. 1). This 
result proves the method of measurement was ap-
propriate for this study. We chose 300 μL plasma 
as the proper volume for subsequent RT-qPCR 
experiments according to the experiment result.
Literature screening of additional  
candidate reference genes
We conducted a PubMed search of the pub-
lished literature to identify traditionally utilized 
reference genes in miRNA research. We narrowed 
the search strategy by limiting our considera-
tion of articles by publication date (from 2008 to 
2015) and language (English). Keywords included: 
“microRNA/miRNA” and “reference gene/house-
keeping gene/internal control/normalize/normali-
zation”. Finally, one small nuclear RNA (RNU6 
[17–19]) and five housekeeping miRNAs (hsa- 
-miR-16-5p [20], hsa-let-7d-5p [10], hsa-miR-484 
[21], hsa-miR-191-5p [22], and hsa-miR-423 [23]) 
were selected as candidate reference genes based 
on the recording frequency during literature 
screening. They were all commonly used refer-
ence genes in analyzing tissue/cell miRNA. Some 
reports also indicate that RNU6, miR-484, let-7d, 
miR-16, and miR-191 can be utilized in some 
serum samples.
Selection of the most stable reference 
genes by Agilent miRNA arrays
We screened stable plasma miRNAs by Agi-
lent miRNA arrays. Sixteen plasma samples were 
analyzed, including 8 healthy and 8 CAD patients. 
Candidate miRNAs were chosen if they fulfilled 
the following criteria: (1) express in all samples, 
share similar properties in patients and controls 
(p > 0.05); (2) highly expressed, have compa-
rable abundance to other miRNAs (the average 
hybridization intendity > 9). According to these 
criteria, 4 miRNAs (hsa-miR-6090,hsa-miR-4516, 
hsa-miR-6089, hsa-miR-3960) were selected as 
candidate reference genes (Fig. 2).
Figure 1. Correlation of plasma volume with the quantifi-
cation cycle (Cq) values. The levels of plasma miR-6090 
were assessed by reverse transcription quantitative poly- 
merase chain reaction. The regression curve between 
Cq values and plasma volume showed a good linear 
relationship (R2 = 0.9694) when the Cq values were 
between 25 and 45. The volume of plasma ranged from 
50 µL to 400 µL (n = 5). Each point represents the mean 
of duplicate measurements.
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Confirmation of candidate reference  
genes by RT-qPCR
Ten candidate reference genes (hsa-miR-6090, 
hsa-miR-4516, hsa-miR-6089, hsa-miR-3960, hsa-
-miR-484, hsa-miR-16-5p, hsa-let-7d-5p, hsa-miR-
191-5p, hsa-miR-423, RNU6) were further evalu-
ated by RT-qPCR assay in 21 stable CAD patients 
and 21 healthy controls (Fig. 3). Expression of 
hsa-let-7d-5p, hsa-miR-191-5p hsa-miR-423 and 
RNU6 were relatively low, with median Cq from 
32 to 39, and even were not detected in some plasma 
samples. Whereas hsa-miR-484, hsa-miR-3960, 
hsa-miR-4516 and hsa-miR-6089 were moderately 
abundant with median Cq of 31.77, 33.23, 31.50 
and 29.98, respectively. hsa-miR-6090 and hsa-
-miR-16-5p were most abundant, with a median 
Cq of 28.71 and 28.45, respectively. Thus, hsa- 
-let-7d-5p, hsa-miR-191-5p and hsa-miR-423 were 
excluded from further analysis because of their 
low expression. Considering RNU6 was widely 
used in tissue/cell miRNA qPCR experiment, we 
Figure 2. The average expression values (hybridization 
intensities ± standard deviations) of the selected miR-
NAs were plotted. Significance was calculated by t-test 
or Mann-Whitney U-test. No differences were found 
between miRNAs of the patients and healthy controls 
(p > 0.05).
Figure 3. Primary quantification cycle (Cq) values of candidate reference miRNAs in all samples. No significant differ-
ences were found between miRNAs of the patients and healthy controls (p > 0.05).
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reserved it in the last analysis. The NormFinder 
and BestKeeper algorithms were performed to 
rank the rest of candidate reference genes accord-
ing to their expression stabilities. There was no 
evidence for differential expression of candidate 
reference miRNAs between stable CAD patients 
and healthy controls (p > 0.05).
hsa-miR-6090 and hsa-miR-4516 had the low-
est stability values which mean the most stable 
expression levels and thus were selected as the 
best combination of reference genes (Table 2). In 
contrast, hsa-miR-484, hsa-miR-16-5p and RNU6, 
the most commonly used reference genes for 
miRNA RT-qPCR normalization, ranked behind 
hsa-miR-6090 and hsa-miR-4516 (Table 2). The 
above results indicate hsa-miR-6090 was the most 
stable reference gene. Moreover, RNU6 was the 
least stable reference gene.
The identified optimal reference gene, hsa- 
-miR-6090 and hsa-miR-4516, were subsequently 
validated in a large sample set containing 
90 healthy controls and 90 stable CAD patients. As 
shown in Figure 4, the expression levels of hsa-
miR-6090 and hsa-miR-4516 remained constant 
across CAD patients and controls. No significant 
differences were detected.
Quantification of plasma miRNAs  
is significantly influenced by different  
normalization approaches
We have tested the accuracy of hsa-miR-6090 
and hsa-miR-4516 as reference genes by using 
exogenous miRNA (spiked-in cel-miR-39) as 
a target. cel-miR-39 was spiked into two groups 
of plasma samples (2 μL per sample) after the 
addition of denaturing solution. Then, total RNA 
was isolated and the relative expression levels of 
cel-miR-39 were calculated by normalization with 
hsa-miR-6090, hsa-miR-16-5p, hsa-miR-4516, hsa-
miR-484 and RNU6, individually. Normalization with 
hsa-miR-6090 produced the most consistent results 
compared with the initial input (Fig. 5). The results 
indicate that normalization to hsa-miR-6090 is a su-
perior normalization method as it corrects technical 
variations better than existing methods and achieves 
accurate identification where others do not.
Furthermore, endogenous miR-21 was selected 
as targets because they have been shown to be el-
evated in aortic stenosis patients [24]. We assessed 
the relative expression levels of miR-21 in the 
plasma of patients and controls by hsa-miR-6090, 
hsa-miR-4516, and RNU6, respectively. The miRNA 
was considered to be significantly up regulated when 
a mean fold change > 2. Normalization with hsa-
miR-6090 or hsa-miR-4516 revealed significant up 
regulated of miR-21 in plasma from patients compared 
with controls (Fig. 6). Normalization with RNU6 re-
vealed no significant differences in miR-21 levels in 
plasma from patients versus controls (Fig. 6). 
The results further indicate that different 
normalization strategies greatly influence the 
consequence: the use of stable genes for normali-
zation will improve sensitivity and reproducibility, 
whereas the choice of unstable reference genes can 
lead to inaccurate results.
Discussion
More and more evidence indicate circulat-
ing miRNAs play important roles in pathological 
Table 2. Evaluation of expression stability of candidate reference miRNAs in stable coronary artery  
disease patients and healthy controls.
Rank NormFinder BestKeeper
miRNA Stability miRNA Stability
Patients Controls Patients Controls
1 miR-6090/4516 0.003 0.005 miR-6090/4516 1.62 1.45
2 hsa-miR-6090 0.008 0.004 hsa-miR-6090 1.49 1.28
3 hsa-miR-4516 0.009 0.014 hsa-miR-4516 1.75 1.34
4 hsa-miR-6089 0.027 0.015 hsa-miR-6089 2.03 1.40
5 hsa-miR-3960 0.030 0.019 hsa-miR-484 1.67 1.54
6 hsa-miR-484 0.031 0.039 hsa-miR-3960 1.70 1.26
7 hsa-miR-16-5p 0.040 0.065 hsa-miR-16-5p 1.92 2.4
8 RNU6 0.067 0.049 RNU6 1.92 2.08
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Figure 4. Expression levels of miR-6090/miR-4516 in large numbers of plasma samples; A. The expression levels of 
miR-6090/miR-4516 were measured in the plasma from stable coronary artery disease patients (n = 90) and healthy 
controls (n = 90). Each point represents the mean of duplicate measurements; PmiR — sample from a patient; 
CmiR — sample from control subject; CV — coefficient of variation; B. The expression values were showed by mean 
quantification cycle (Cq) values ± standard deviations; significances were calculated by t-test or Mann-Whitney 
U-test; no significant differences were found between miRNAs from the patients and healthy controls (p > 0.05).
Figure 5. Effects of different normalization methods on the expression levels of plasma miRNAs. Plasma samples from 
stable coronary artery disease patients and healthy controls were divided into two groups (n = 5 in each group). 2 µL 
artificial miRNA cel-39 was spiked into 300 µL plasma of each group. The levels of artificial miRNA were assessed by 
reverse transcription quantitative polymerase chain reaction and were normalized to miR-16, miR-6090, miR-4516, 
miR-484, and RNU6, respectively. Significance was calculated by t-test or U test.
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Figure 6. Expression levels of miR-21 were measured 
in plasma from stable coronary artery disease patients 
(n = 30) and healthy controls (n = 30) by quantitative 
polymerase chain reaction and were normalized to miR-
-6090, miR-4516 and RNU6, respectively. Relative levels 
were calculated using the 2-DDCq method and were pre-
sented as mean fold changes ± standard errors. Signifi-
cance was calculated by t-test and Mann-Whitney U test.
processes and can serve as candidate biomarkers 
in multiple conditions. qPCR is an important tech-
nology to studying circulating miRNAs. The high 
sensitivity of qPCR demands a suitable reference 
gene to correct the non-biological variation.
An ideal endogenous control gene should be 
expressed at a constant level across all samples, 
exhibit relatively stable expression levels between 
samples and groups, and have no known association 
with the disease under investigation. Traditionally 
used endogenous reference genes for tissue/cell 
miRNAs were not suitable to normalize circulating 
miRNA levels because they are not miRNAs. The 
efficiency of their extraction, reverse transcription 
and PCR amplification may differ from that of circu-
lating miRNAs. Some research even indicated that 
these genes varied significantly in serum and were 
unstable even after short-term storage [10]. RNU6 
is a most commonly used reference gene in tissue/
cell samples. But in our study, its expression level 
in plasma was very low (Fig. 3), and could not be de-
tected in some plasma samples. Its expression level 
was least stable comparing with other candidate 
controls (Table 2). These results confirmed recent 
findings that RNU6 was not stably expressed in 
plasma/serum samples and is not a suitable control 
[6, 25]. miR-16 is also a universal reference gene 
because of its high expression level. But some 
recent studies reported up-regulation of miR-16 
in plasma in some diseases, such as autoimmune 
thyroid disease [26], experimental sepsis [27] and 
gastric cancer [28]. Other research demonstrated 
that miR-16 is highly expressed in red blood cells 
so that any hemolysis of blood samples strongly af-
fects their level in plasma [29]. In our research, we 
also found variable expression of miR-16 between 
individuals, and miR-16 showed the lowest stability 
in the candidate miRNAs we detected (Table 2). 
Synthetic non-human (e.g., C. elegans) miRNAs is 
also usually used as spike-in controls to normalize 
circulating miRNA. However, spike-in controls 
can only correct the technical variability in RNA 
extraction and PCR efficiency, but cannot correct 
for variability in sample collection and storage [10]. 
Indeed, the spiked exogenous C. elegans miRNAs, 
including cel-miR-39, cel-miR-238 and cel-miR-54, 
did not significantly improve assay precision in 
some reports [30]. Therefore, spike-in controls 
are also not an ideal reference gene.
Circulating miRNAs themselves share similar 
properties, such as stability and purification pro-
cedure. So it may be the most suitable method for 
nermalization. In our study, 10 candidate reference 
miRNAs were selected based on literature screen-
ing and miRNA arrays. RT-qPCR results indicated 
that let-7d, miR-191, miR-423 were not good refer-
ence genes because of their low abundances (Fig. 3). 
The stabilities of the rest miRNAs were further 
investigated using the NormFinder and BestKeep-
er methods. Whereas there were slightly differ-
ent in the result of NormFinder and BestKeeper, 
miR-6090 was ranked as the most stable reference 
gene by both NormFinder and BestKeeper (Table 2). 
The effect of different normalization strategies 
was compared. When the data were normalized to 
miR-6090, miR-4516, significant differences were 
detected between patients and controls. However, 
when the data were normalized to RNU6, there was 
no significant difference (Fig. 6).
Our study shows that miR-6090 and miR- 
-4516 could serve as reference miRNAs for qPCR 
analysis of plasma miRNA in stable CAD patients 
and healthy controls. Additionally, it is an essential 
component in accurately analyzed qPCR data.
We noticed that sample set 4 was not very 
large. While the assessment of a larger number of 
subjects would clearly be beneficial, the current 
sample sizes may nevertheless be adequate to ad-
dress the conclusion that miR-6090 and miR-4516 
are better controls than RNU6. A good reference 
gene should meet three main criteria: 1) be de-
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tectable in all samples, 2) exhibit stable levels, 
and 3) have similar performance in controls and 
patients. Our results show that miR-6090/4515 
meet all these criteria and perform better than 
RNU6 not only in the experiment from sample 
set 4, but also in experiments from sample set 2 
and 3. Another possible limitation of this study is 
that we only detected the expression of reference 
gene in stable CAD. Since other types of CAD, 
such as acute coronary syndrome, may significantly 
alter miRNAs release into plasma, they need to 
be discussed separately. The possibility of miR-
6090/4516 use in other types of CAD deserves fur-
ther exploration in the future. The third limitation 
is we isolated RNAs by using TRIzol LS reagent. 
Furthermore, we found miR-6090 performed better 
(with lower Cq values) by using miRNeasy Mini 
kit. So, if miR-6090 can be used as reference gene 
in the future, we recommend extracting RNA by 
miRNeasy Mini kit.
Conclusions
In conclusion, we found that the traditionally-
used EC, RNU6, are not suitable for circulating 
miRNA normalization because of their low expres-
sion (mean Cq value = 34.65) and low stability 
(0.067 or 1.92 in patients, 0.049 or 2.08 in controls) 
calculated by NormFinder and BestKeeper algo-
rithm. Finally, our results suggest two miRNAs, 
miR-6090 and miR-4516, can be used as reference 
genes for stable CAD plasma miRNA analysis.
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